CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to REGN

VEGF Trap-Eye 2.0mg

Phase 3
Regeneron Pharmaceuticals, Inc. (REGN)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Macular Edema Secondary to Central Retinal Vein Occlusion

View Full Landscape
Drug Information

Target Indication

Macular Edema Secondary to Central Retinal Vein Occlusion

Clinical Trial

NCT00943072

Last updated: 1/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.